Immunoclin (Immunoclin) EBIT per Share : $-0.12 (TTM As of Oct. 2014)

View and export this data going back to 2012. Start your Free Trial

What is Immunoclin EBIT per Share?

Immunoclin's EBIT per Share for the three months ended in Oct. 2014 was $-0.04. Its EBIT per Share for the trailing twelve months (TTM) ended in Oct. 2014 was $-0.12.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Immunoclin's EBIT per Share or its related term are showing as below:

IMCL's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Immunoclin's EBIT for the three months ended in Oct. 2014 was $-1.15 Mil.

Immunoclin EBIT per Share Historical Data

The historical data trend for Immunoclin's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunoclin EBIT per Share Chart

Immunoclin Annual Data

Trend

Feb12

Jan13

Jan14

EBIT per Share

-0.02

-0.03

-1.21

Immunoclin Quarterly Data
	May11	Aug11	Nov11	Feb12	May12	Aug12	Nov12	Feb13	May13	Aug13	Nov13	Apr14	Jul14	Oct14
EBIT per Share	Get a 7-Day Free Trial									-0.01	-0.01	-0.03	-0.04	-0.04

Immunoclin EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Immunoclin's EBIT per Share for the fiscal year that ended in Jan. 2014 is calculated as

	EBIT per Share		(A: Jan. 2014 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-12.982	/	10.775
=	-1.20

Immunoclin's EBIT per Share for the quarter that ended in Oct. 2014 is calculated as

	EBIT per Share		(Q: Oct. 2014 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.154	/	27.896
=	-0.04

EBIT per Share for the trailing twelve months (TTM) ended in Oct. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12

Immunoclin (GREY:IMCL) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Immunoclin EBIT per Share Related Terms

Thank you for viewing the detailed overview of Immunoclin's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunoclin (Immunoclin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunoclin Corp (GREY:IMCL) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

9107 Wilshire Boulevard, Suite 450, Beverly Hills, CA, USA, 90210

Website

http://www.immunoclin.com

Immunoclin Corp is engaged in immunology research and development skill to serve the pharmaceutical, biotechnology and food industries, providing comprehensive, clinical and basic science research expertise at a commercial scale and quality.

Immunoclin (Immunoclin) Headlines

No Headlines